Capecitabine is an oral fluoropyrimidine antineoplastic agent used in breast, gastric, and colorectal cancers. It is converted in the body to 5-fluorouracil and is commonly used in combination regimens or selected monotherapy settings. It is marketed under brand names including Xeloda and is prescription-only.
Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07590024 |
RAIRI-Guided Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
RECRUITING | PHASE3 |
| NCT07582315 |
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07580339 |
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570914 |
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases |
NOT_YET_RECRUITING | PHASE2 |
| NCT07562711 |
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer |
RECRUITING | PHASE2 |
| NCT07562659 |
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer |
RECRUITING | PHASE2 |
| NCT07561060 |
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy |
RECRUITING | PHASE1/PHASE2 |
| NCT07554521 |
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States |
RECRUITING | PHASE2 |
| NCT07551479 |
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07549906 |
Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study |
NOT_YET_RECRUITING | PHASE2 |
